TOREMIFENE INCREASES BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER: INTERIM ANALYSIS OF A MULTICENTER PHASE 3 CLINICAL STUDY

PURPOSE: To evaluate the effects of toremifene on bone mineral density (BMD), a surrogate for fracture risk, in men receiving androgen deprivation therapy (ADT) for prostate cancer. MATERIALS AND METHODS: In an ongoing, multicenter, Phase 3 fracture prevention study, 1392 men ≥ 50 years old with pro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Smith, MR, Malkowicz, S Bruce, Chu, F, Forrest, J, Price, D, Sieber, P, Barnette, KG, Rodriguez, D, Steiner, MS
Format: Artigo
Idioma:Inglês
Publicat: 2007
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3090686/
https://ncbi.nlm.nih.gov/pubmed/18001802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2007.08.137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars